127 related articles for article (PubMed ID: 27100894)
1. Discovery of a novel target for renal cell carcinoma: transglutaminase 2.
Kang JH; Lee SH; Kim SY
Cell Death Dis; 2016 Apr; 7(4):e2200. PubMed ID: 27100894
[No Abstract] [Full Text] [Related]
2. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY
Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
Jang JH; Park JS; Lee TJ; Kwon TK
Cancer Lett; 2010 Jan; 287(2):224-30. PubMed ID: 19632032
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.
Lee SH; Kang JH; Ha JS; Lee JS; Oh SJ; Choi HJ; Song J; Kim SY
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708896
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Kang JH; Lee SH; Lee JS; Oh SJ; Ha JS; Choi HJ; Kim SY
Cells; 2020 Jun; 9(6):. PubMed ID: 32560270
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells.
Huaying S; Dong Y; Chihong Z; Xiaoqian Q; Danying W; Jianguo F
Med Sci Monit; 2016 Dec; 22():5041-5048. PubMed ID: 28002389
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
10. Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors.
Kim N; Kwak SH; Lee SH; Juvekar V; Lee BI; Ahn HC; Kim SY; Gong YD
Org Biomol Chem; 2014 Jul; 12(27):4932-40. PubMed ID: 24879506
[TBL] [Abstract][Full Text] [Related]
11. GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3).
Hitomi K; Ikura K; Maki M
Biosci Biotechnol Biochem; 2000 Mar; 64(3):657-9. PubMed ID: 10803976
[TBL] [Abstract][Full Text] [Related]
12. Irreversible inhibitors of tissue transglutaminase.
Keillor JW; Chabot N; Roy I; Mulani A; Leogane O; Pardin C
Adv Enzymol Relat Areas Mol Biol; 2011; 78():415-47. PubMed ID: 22220480
[No Abstract] [Full Text] [Related]
13. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.
Pardin C; Roy I; Lubell WD; Keillor JW
Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232
[TBL] [Abstract][Full Text] [Related]
14. Tissue transglutaminase: an emerging target for therapy and imaging.
Pietsch M; Wodtke R; Pietzsch J; Löser R
Bioorg Med Chem Lett; 2013 Dec; 23(24):6528-43. PubMed ID: 24432384
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapies for renal cell cancer: TRAIL research advances.
Buttyan R; Mian BM
J Urol; 2007 May; 177(5):1606. PubMed ID: 17437767
[No Abstract] [Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
17. A sensitive fluorometric assay for tissue transglutaminase.
Jeitner TM; Fuchsbauer HL; Blass JP; Cooper AJ
Anal Biochem; 2001 May; 292(2):198-206. PubMed ID: 11355851
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma.
Erdem M; Erdem S; Sanli O; Sak H; Kilicaslan I; Sahin F; Telci D
Urol Oncol; 2014 Jan; 32(1):25.e13-20. PubMed ID: 23499501
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Déjosez M; Ramp U; Mahotka C; Krieg A; Walczak H; Gabbert HE; Gerharz CD
Cell Death Differ; 2000 Nov; 7(11):1127-36. PubMed ID: 11139287
[TBL] [Abstract][Full Text] [Related]
20. Medullary renal cell carcinoma and response to therapy with bortezomib.
Ronnen EA; Kondagunta GV; Motzer RJ
J Clin Oncol; 2006 Mar; 24(9):e14. PubMed ID: 16549825
[No Abstract] [Full Text] [Related]
[Next] [New Search]
